Identification and selection of health technologies for assessment by agencies in support of reimbursement decisions in Latin America.

Biomedical Decision making Health priorities Health resources Latin America Technology assessment

Journal

International journal of technology assessment in health care
ISSN: 1471-6348
Titre abrégé: Int J Technol Assess Health Care
Pays: England
ID NLM: 8508113

Informations de publication

Date de publication:
16 Aug 2021
Historique:
entrez: 16 8 2021
pubmed: 17 8 2021
medline: 26 10 2021
Statut: epublish

Résumé

There is no health system that has the resources to evaluate all technologies. The presence of a clear process to prioritize health technologies for assessment by health technology assessment (HTA) agencies is a good practice principle recognized at the international level. The objective of Health Technology Assessment International's 2020 Latin American Policy Forum (LatamPF) was to explore how to improve the way HTA agencies in Latin America identify and prioritize technologies for assessment. This paper is based on a background document, a survey, and the deliberations of the members of the LatamPF (forty-six participants from eleven countries) using a design thinking methodology. Participants agreed that a lack of clear prioritization mechanisms results in HTA processes and decisions that are perceived to be of low transparency and overly exposed to political or interest group pressures. The LatamPF identified barriers and recommended actions to improve HTA prioritization mechanisms in Latin America. The criteria identified as the most important to be taken into consideration by HTA agencies in the region when prioritizing a technology for assessment were: the burden of illness, the potential clinical benefit, the alignment with national health priorities, the potential impact on equity, a lack of treatment alternatives for patients, and the potential economic impact. Forum participants agreed that the establishment of transparent prioritization processes is a key element for all health systems. Improvements in these processes will strengthen HTA and provide greater legitimacy to decision making.

Identifiants

pubmed: 34392842
doi: 10.1017/S0266462321000416
pii: S0266462321000416
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e80

Auteurs

Andrés Pichon-Riviere (A)

Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina.

Federico Augustovski (F)

Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina.

Sebastián García Martí (S)

Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina.

Andrea Alcaraz (A)

Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina.

Verónica Alfie (V)

Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina.

Laura Sampietro-Colom (L)

Unidad de Evaluación Innovaciones y Nuevas Tecnologías, Dirección Investigación&Innovación, Hospital Clinic de Barcelona, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH